Keybanc Maintains Overweight on Avid Bioservices, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Paul Knight has maintained an Overweight rating on Avid Bioservices (NASDAQ:CDMO) but has reduced the price target from $20 to $14. This adjustment reflects a change in valuation expectations for the company.

December 08, 2023 | 9:22 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avid Bioservices' stock may experience short-term pressure due to the lowered price target from $20 to $14 by Keybanc, despite maintaining an Overweight rating.
A reduction in price target typically indicates a change in the expected future performance of a company. Although the Overweight rating suggests that Keybanc still sees positive prospects for Avid Bioservices, the lowered price target may lead to short-term negative sentiment among investors, potentially causing a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100